Lercanidipine Viatris

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Viatris, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat hypertension in adult patients.

GNH USA supplies Lercanidipine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker indicated for the management of high blood pressure. - Hypertension: lowers systolic and diastolic blood pressure in adults with essential hypertension, helping to reduce cardiovascular risk.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, often on the face. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially on standing. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare but serious cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: dose adjustment may be required. - Elderly patients: start at low dose and monitor closely. - Concomitant antihypertensives: risk of additive hypotensive effect. - CYP3A4 inhibitors: avoid strong inhibitors that may increase exposure. - Store at room temperature: keep in the original pack, protect from moisture.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels. - Grapefruit juice: can increase drug exposure. - Other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness. - Diuretics: may enhance antihypertensive effect. - Beta‑blockers: additive blood‑pressure lowering. - NSAIDs: may blunt antihypertensive response. - Digoxin: monitor for potential changes in serum concentration.